Skip to main content

Table 1 Demographic characteristics of the per-protocol cohort

From: Superior antigen-specific CD4+T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older

Characteristic

TIV/AS03(≥65)

TIV(≥65)

TIV(18–40)

Total

 

(N = 62)

(N = 66)

(N = 44)

(N = 172)

Age, months; mean (SD)

71.4 (5.5)

71.3 (5.3)

26.3 (5.1)

59.8 (20.4)

Gender; n (%)

Female

31 (50)

27 (41)

24 (55)

82 (48)

Male

31 (50)

39 (59)

20 (46)

90 (52)

Race; n (%)

American Indian or Alaskan native

0 (0)

0 (0)

0 (0)

0 (0)

African heritage/African American

0 (0)

0 (0)

0 (0)

0 (0)

Asian–Central/S. Asian heritage

0 (0)

0 (0)

2 (4.5)

2 (1.2)

Asian–E. Asian heritage

0 (0)

0 (0)

2 (4.5)

2 (1.2)

Asian–Japanese heritage

0 (0)

0 (0)

0 (0)

0 (0)

Asian–S. E. Asian heritage

0 (0)

1 (1.5)

1 (2.3)

2 (1.2)

Native Hawaiian/pacific islander

0 (0)

0 (0)

0 (0)

0 (0)

White - Arabic/N. African heritage

0 (0)

0 (0)

1 (2.3)

1 (0.6)

White - Caucasian/European heritage

62 (100)

64 (97)

37 (84)

163 (95)

 

Other

0 (0)

1 (1.5)

1 (2.3)

2 (1.2)

  1. SD, standard deviation; TIV, trivalent influenza vaccine; TIV/AS03, AS03-adjuvanted trivalent influenza vaccine.